Our findings suggest that older adults with elevated NfL levels are particularly vulnerable to ACD‐related cognitive impairment, and plasma NfL testing may guide deprescribing of high‐risk ACDs in older adults, prioritizing non‐anticholinergic alternatives to mitigate dementia risk. This evidence concerns the gene NEFL and dementia.